A. Yassen

发表

Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats.

M. Danhof, A. Dahan, E. Olofsen, 2005, British journal of anaesthesia.

Pharmacokinetic–Pharmacodynamic Modeling of the Effectiveness and Safety of Buprenorphine and Fentanyl in Rats

Erik Olofsen, Albert Dahan, Meindert Danhof, 2007, Pharmaceutical Research.

Mechanism‐based PK/PD Modeling of the Respiratory Depressant Effect of Buprenorphine and Fentanyl in Healthy Volunteers

M. Danhof, A. Dahan, E. Olofsen, 2007, Clinical pharmacology and therapeutics.

Mechanism-based pharmacokinetic-pharmacodynamic modeling of the efficacy and safety of (semi-)synthetic opioids

A. Yassen, 2007 .

Pharmacokinetic–pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature

Erik Olofsen, Albert Dahan, A. Dahan, 2011, Expert review of clinical pharmacology.

Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics

M. Danhof, A. Dahan, E. Olofsen, 2005, Journal of Pharmacology and Experimental Therapeutics.

Buprenorphine induces ceiling in respiratory depression but not in analgesia.

M. Danhof, A. Dahan, E. Olofsen, 2006, British journal of anaesthesia.

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics

A. Yassen, K. Thelen, S. Schwers, 2019, Research and practice in thrombosis and haemostasis.

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

A. Yassen, S. Schwers, F. Kanefendt, 2021, Journal of thrombosis and haemostasis : JTH.

A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female Subjects

P. Reeh, A. Yassen, K. Schaffler, 2017, Pain medicine.

Naloxone Reversal of Buprenorphine-induced Respiratory Depression

M. Danhof, A. Dahan, E. Olofsen, 1988, Anesthesiology.

Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats

M. Danhof, A. Dahan, E. Olofsen, 2007, Journal of Pharmacology and Experimental Therapeutics.

First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development

M. Danhof, T. Eissing, J. Freijer, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Translational PK–PD modeling in pain

A. Dahan, Y. Furuichi, A. Yassen, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

A Semiphysiological Population Model for Prediction of the Pharmacokinetics of Drugs under Liver and Renal Disease Conditions

M. Danhof, J. Freijer, W. Krauwinkel, 2011, Drug Metabolism and Disposition.

Microsoft Word-89773423-file00

M. Danhof, J. Freijer, W. Krauwinkel, 2011 .

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men

A. Yassen, S. Schwers, Stefanie Boxnick, 2022, Journal of thrombosis and haemostasis : JTH.

Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups

Erik Olofsen, Albert Dahan, A. Dahan, 2012, Journal of pain research.

Naloxone treatment in opioid addiction: the risks and benefits

Albert Dahan, A. Dahan, A. Yassen, 2007, Expert opinion on drug safety.

Mechanism-Based Pharmacokinetic-Pharmacodynamic Modelling of the Reversal of Buprenorphine-Induced Respiratory Depression by Naloxone

M. Danhof, A. Dahan, E. Olofsen, 2007, Clinical pharmacokinetics.

A novel approach to identify responder subgroups and predictors of response to low‐ and high‐dose capsaicin patches in postherpetic neuralgia

A. Dahan, E. Olofsen, C. Martini, 2013, European journal of pain.

Guidelines for the Quality Control of Population Pharmacokinetic–Pharmacodynamic Analyses: an Industry Perspective

P. Bonate, S. Tannenbaum, A. Yassen, 2012, The AAPS Journal.

Predicting the “First dose in children” of CYP3A‐metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7‐CYP3A4 switch at young ages

M. Danhof, J. Freijer, C. Monnereau, 2014, Journal of clinical pharmacology.

First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development

M. Danhof, T. Eissing, J. Freijer, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Mechanism-based Pharmacokinetic–Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine in Healthy Volunteers

Erik Olofsen, Albert Dahan, Meindert Danhof, 2006, Anesthesiology.

Translational PK–PD modeling in pain

A. Dahan, Y. Furuichi, A. Yassen, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

Morphine‐6‐glucuronide (M6G) for postoperative pain relief

A. Dahan, A. Yassen, Terry W. Smith, 2008, European journal of pain.

Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats

M. Danhof, A. Dahan, E. Olofsen, 2006, Journal of Pharmacology and Experimental Therapeutics.

Animal-to-Human Extrapolation of the Pharmacokinetic and Pharmacodynamic Properties of Buprenorphine

M. Danhof, A. Dahan, E. Olofsen, 2007, Clinical pharmacokinetics.

Buprenorphine induces ceiling in respiratory depression but not in analgesia.

M. Danhof, A. Dahan, E. Olofsen, 2006, British Journal of Anaesthesia.

Mechanism-based Pharmacokinetic–Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine in Healthy Volunteers

M. Danhof, A. Dahan, E. Olofsen, 2006, Anesthesiology.